Physician profile
Maria Collado
NPI 1053340786
$1,725.64
in general payments reported to CMS, 2019-2025
25 companies · $453 in 2025
The $453 reported for 2025 was more than what 92% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $225 · 2021: $167 · 2022: $289 · 2023: $226 · 2024: $135 · 2025: $453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cranial Technologies, INC | $352.99 | 2019-2025 | Doc Band |
| Kowa Pharmaceuticals America, INC. | $245.74 | 2025 | Zoryve |
| Kaleo, INC. | $202.75 | 2019-2023 | Auvi-Q |
| Genentech USA, INC. | $115.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $111.43 | 2022 | |
| Aytu Biopharma, INC. | $88.26 | 2020-2022 | |
| Sanofi Pasteur INC. | $73.69 | 2019-2024 | |
| Pfizer INC. | $64.84 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $61.88 | 2020 | |
| Alk-Abello, INC | $59.43 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $56.41 | 2020-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Ars Pharmaceuticals Operations, INC. | $30.87 | 2025 | Neffy |
| Arbor Pharmaceuticals, INC. | $29.82 | 2019 | |
| Hologic Sales and Service, LLC | $27.93 | 2019-2021 | |
| Seqirus USA INC | $27.58 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24.01 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.71 | 2025 | Koselugo |
| Phadia US INC. | $21.39 | 2023 | Immunocap |
| Verrica Pharmaceuticals INC. | $18.92 | 2024 | Ycanth |
| Neos Therapeutics, LP | $18.57 | 2021 | |
| Lnhc, INC | $16.00 | 2025 | Zelsuvmi |
| Xeris Pharmaceuticals, INC. | $14.89 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.64 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $13.16 | 2024 | Flumist Quadrivalent |
| Tris Pharma INC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Collado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.